5-羟甲基胞嘧啶与肿瘤

doi:10.11904/j.issn.1002-3070.2021.04.017

摘要/Abstract

摘要： 肿瘤的发生发展和侵袭与表观遗传学变化紧密相关。胞嘧啶甲基化产物5-甲基胞嘧啶(5-methylcytosine,5-mC)是重要的表观遗传学调控因子。羟甲基化是5-mC去甲基化的重要过程之一,其产物5-羟甲基胞嘧啶(5-hydroxymethylcytosine,5-hmC)也参与基因的表观遗传学调控。国内外研究提示,5-hmC表达水平及分布的改变与胚胎发育、肿瘤发生发展等密切相关。本文对5-hmC及其在肿瘤中的异常与肿瘤关系的研究进展进行综述。

关键词: 肿瘤, DNA羟甲基化, 5-hmC

Abstract: The occurrence,development and invasion of tumors are closely related to epigenetic changes.5-Methylcytosine(5-mC),a product of cytosine methylation,is an important epigenetic regulator.Hydroxymethylation is one of the important processes of 5-mC demethylation,and its product 5-hydroxymethylcytosine(5-hmC)is also involved in the epigenetic regulation of genes.Multiple studies at domestic and foreign suggest that the changes of 5-hmC level and distribution are closely related to embryonic development and tumorigenesis.This article reviews the research progress of 5-hmC and its abnormality in tumor and its relationship with tumor.

Key words: Tumor, DNA hydroxymethylation, 5-Hydrosymethylcytosine

中图分类号:

R730.43

刘双庆, 车德海, 孟庆威. 5-羟甲基胞嘧啶与肿瘤[J]. 实用肿瘤学杂志, 2021, 35(4): 386-390.

LIU Shuangqing, CHE Dehai, MENG Qingwei. 5-Hydroxymethylcytosine and tumor[J]. Journal of Practical Oncology, 2021, 35(4): 386-390.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.04.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I4/386

参考文献

1 Yu M,Hazelton WD,Luebeck GE,et al.Epigenetic aging:more than just a clock when it comes to cancer[J].Cancer Res,2020,80(3):367-374.
2 Kumar S,Chinnusamy V,Mohapatra T.Epigenetics of modified DNA bases:5-methylcytosine and beyond[J].Front Genet,2018,9:640.
3 Wu X,Zhang Y.TET-mediated active DNA demethylation:mechanism,function and beyond[J].Nat Rev Genet,2017,18(9):517-534.
4 Li W,Xu L.Epigenetic function of TET family,5-methylcytosine,and 5-hydroxymethylcytosine in hematologic malignancies[J].Oncol Res Treat,2019,42(6):309-318.
5 Pfeifer GP,Szabó PE,Song J.Protein interactions at oxidized 5-methylcytosine bases[J].J Mol Biol,2019,2836(19)30501-30507.
6 Kohli RM,Zhang Y.TET enzymes,TDG and the dynamics of DNA demethylation[J].Nature,2013,502(7472):472-479.
7 Kochmanski J,Bernstein AI.The impact of environmental factors on 5-hydroxymethylcytosine in the brain[J].Curr Environ Health Rep,2020,7(2):109-120.
8 López V,Fernández AF,Fraga MF.The role of 5-hydroxymethylcytosine in development,aging and age-related diseases[J].Ageing Res Rev,2017,37:28-38.
9 Smeets E,Lynch AG,Prekovic S,et al.The role of TET-mediated DNA hydroxymethylation in prostate cancer[J].Mol Cell Endocrinol,2018,462:41-55.
10 Wang J,Su Y,Tian Y,et al.Characterization of DNA hydroxymethylation profile in cervical cancer[J].ARTIF Cell Nanomed B,2019,47(1):2706-2714.
11 Kristensen G,Strand SH,Røder MA,et al.5hmC level predicts biochemical failure following radical prostatectomy in prostate cancer patients with ERG negative tumors[J].Int J Mol Sci,2019,20(5):1025.
12 Bonvin E,Radaelli E,Bizet M,et al.TET2-dependent hydroxymethylome plasticity reduces melanoma initiation and progression[J].Cancer Res,2019,79(3):482-494.
13 Cai J,Chen L,Zhang Z,et al.Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J].Gut,2019,68(12):2195-2205.
14 Wu J,Li H,Shi M,et al.TET1-mediated DNA hydroxymethylation activates inhibitors of the Wnt/beta-catenin signaling pathway to suppress EMT in pancreatic tumor cells[J].J Exp Clin Cancer Res,2019,38(1):348.
15 Li X,Liu Y,Salz T,et al.Whole-genome analysis of the methylome and hydroxymethylome in normal and malignant lung and liver[J].Genome Res,2016,26(12):1730-1741.
16 Chen Q,Yin D,Zhang Y,et al.MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis[J].Cell Death Dis,2017,8(6):e2906.
17 Lian CG,Xu Y,Ceol C,et al.Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma[J].Cell,2012,150(6):1135-1146.
18 Peng D,Ge G,Gong Y,et al.Vitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer[J].Clin Epigenetics,2018,10(1):94.
19 Shi DQ,Ali I,Tang J,et al.New insights into 5hmc DNA modification:generation,distribution and function[J].Front Genet,2017,8:100.
20 Mahajan NP,Malla P,Bhagwat S,et al.WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression[J].Oncotarget,2017,8(63):106352-106368.
21 Fu S,Wu H,Zhang H,et al.DNA methylation/hydroxymethylation in melanoma[J].Oncotarget,2017,8(44):78163-78173.
22 Liu J,Jiang J,Mo J,et al.Global dna 5-hydroxymethylcytosine and 5-formylcytosine contents are decreased in the early stage of hepatocellular carcinoma[J].Hepatology,2019,69(1):196-208.
23 Wang P,Yan Y,Yu W,et al.Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma[J].Cell Prolif,2019,52(4):e12626.
24 Song CX,Yin S,Ma L,et al.5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages[J].Cell Res,2017,27(10):1231-1242.
25 Zhang J,Han X,Gao C,et al.5-Hydroxymethylome in circulating cell-free DNA as a potential biomarker for non-small-cell lung cancer[J].Genom Proteom Bioinf,2018,16(3):187-199.
26 Fernandez AF,Bayón GF,Sierra MI,et al.Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma[J].Hum Mol Genet,2018,27(17):3046-3059.
27 Zhou Z,Zhang HS,Liu Y,et al.Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated down-regulation of E-cadherin[J].J Cell Physiol,2018,233(2):1359-1369.
28 Che D,Zhang S,Jing Z,et al.Macrophages induce EMT to promote invasion of lung cancer cells through the IL-6-mediated COX-2/PGE(2)/β-catenin signalling pathway[J].Mol Immunol,2017,90:197-210.
29 Ko M,An J,Pastor WA,et al.TET proteins and 5-methylcytosine oxidation in hematological cancers[J].Immunol Rev,2015,263(1):6-21.
30 Hore TA,Von Meyenn F,Ravichandran M,et al.Retinol and ascorbate drive erasure of epigenetic memory and enhance reprogramming to nave pluripotency by complementary mechanisms[J].Proc Natl Acad Sci U S A,2016,113(43):12202-12207.
31 Li C,Dong L,Su R,et al.Homoharringtonine exhibits potent anti-tumor effect and modulates DNA epigenome in acute myeloid leukemia by targeting SP1/TET1/5hmC[J].Haematologica,2020,105(1):148-160.
32 Lio CJ,Yuita H,Rao A.Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies[J].Blood,2019,134(18):1487-1497.
33 Shenoy N,Bhagat TD,Cheville J,et al.Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma[J].J Clin Invest,2019,129(4):1612-1625.

[1]	刘言玉, 李道娟, 梁迪, 师金, 靳晶, 单保恩, 贺宇彤. 2011—2016年河北省肿瘤登记地区食管癌发病和死亡流行情况分析[J]. 实用肿瘤学杂志, 2021, 35(4): 314-320.
[2]	王秦, 林玲, 蔡波, 陶长余, 武鸣, 韩仁强, 罗鹏飞, 俞浩, 缪伟刚, 周金意. 2015年江苏省脑和神经系统肿瘤流行现状及2006—2015年趋势分析[J]. 实用肿瘤学杂志, 2021, 35(4): 321-326.
[3]	武婧, 崔王飞, 曹凌, 郭雪蓉, 马朝辉, 王昕琛, 张瑞锋, 张永贞. 山西省肿瘤登记地区2016年上消化道癌发病与死亡情况分析[J]. 实用肿瘤学杂志, 2021, 35(4): 327-331.
[4]	任思颖, 陈杨, 石青萍, 朱云芳, 文洪梅. 云南省肿瘤登记地区2011—2016年肺癌发病和死亡特征及时间趋势[J]. 实用肿瘤学杂志, 2021, 35(4): 332-338.
[5]	董华, 王定彬, 华婧, 范康琼, 马楠楠, 王兴任. 2016年海南省肿瘤登记地区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2021, 35(4): 344-350.
[6]	黄瑜, 刘玉琴, 丁高恒, 古扎努尔·尼牙孜, 王亮亮, 吴建军. 2009—2015年甘肃省肿瘤登记地区胆囊癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 193-199.
[7]	王亮亮, 丁高恒, 陈莉莉, 吴建军, 刘玉琴, 魏兴民. 2009—2015年甘肃省肿瘤登记地区胰腺癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 200-206.
[8]	郭伟, 朱奕潼, 丁高恒, 朱公建, 刘玉琴, 吴建军. 2009—2015年甘肃省肿瘤登记地区子宫体癌发病与死亡特征分析[J]. 实用肿瘤学杂志, 2021, 35(3): 207-211.
[9]	朱公建, 朱奕潼, 丁高恒, 王宏宗, 杜美霞, 刘玉琴. 2009—2015年甘肃省肿瘤登记地区结直肠癌流性特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 212-217.
[10]	张光耀, 郭伟, 朱奕潼, 丁高恒, 朱公建, 吴建军, 刘玉琴. 2009—2015年甘肃省肿瘤登记地区甲状腺癌流行特征及变化趋势[J]. 实用肿瘤学杂志, 2021, 35(3): 218-223.
[11]	姚丽萍, 王宏宗, 丁高恒, 刘玉琴. 2009—2015年甘肃省肿瘤登记地区宫颈癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 224-230.
[12]	陈莉莉, 刘玉琴, 丁高恒, 苏海翔. 甘肃省恶性肿瘤流行情况及防控现状[J]. 实用肿瘤学杂志, 2021, 35(3): 254-257.
[13]	马明瑞, 连洁, 刘超, 娄长杰, 张艳桥. 消化系统肿瘤“免疫治疗前移”的探索[J]. 实用肿瘤学杂志, 2021, 35(3): 258-262.
[14]	黎敏, 冉立, 常建英. 影像学技术在图像引导宫颈癌近距离放射治疗中的应用[J]. 实用肿瘤学杂志, 2021, 35(3): 263-267.
[15]	国昊楠, 秦韬. MYO10与恶性肿瘤的研究进展[J]. 实用肿瘤学杂志, 2021, 35(3): 273-276.